SkinCure Oncology Executive and Leadership Team

Kerwin Brandt, the Chief Executive Officer at SkinCure Oncology, directs the overarching corporate strategy and long-term vision for non-surgical skin cancer treatment. By expanding the reach of Image-Guided SRT technology, the Chief Executive Officer ensures that dermatology practices nationwide gain access to advanced radiotherapy solutions. This leadership role involves cultivating partnerships with Mohs surgeons to integrate cancer center-level capabilities directly into private offices. Kerwin Brandt maintains focus on scaling the company infrastructure to support over 200 locations while driving consistent growth in patient care standards. Through rigorous oversight of organizational health, the Chief Executive Officer aligns internal resources with the mission of providing accessible, effective treatment options. By prioritizing innovation in healthcare technology, Brandt secures the market position of the firm as a leader in dermatological oncology solutions, ultimately fostering improved clinical outcomes for thousands of patients across the United States.

Perry Baker, the Chief Financial Officer at SkinCure Oncology, manages the fiscal health and capital allocation strategies necessary to support the deployment of Image-Guided SRT technology. Overseeing financial planning and analysis, the Chief Financial Officer ensures that the company maintains the resources required to partner with dermatology practices across the country. This role involves monitoring revenue streams from radiotherapy services and optimizing cost structures to sustain long-term profitability. Perry Baker collaborates with the executive team to evaluate investment opportunities in new medical technologies and infrastructure expansion. By maintaining rigorous financial controls, the Chief Financial Officer provides the stability needed for the organization to scale operations effectively. Through strategic budgeting and risk management, Baker supports the broader goal of increasing patient access to non-surgical cancer treatments. This financial leadership directly enables the company to continue providing high-quality care solutions to dermatologists and their patients in diverse markets nationwide.

Joshua Swindle, the Chief Operating Officer at SkinCure Oncology, executes the operational strategy required to integrate Image-Guided SRT technology into dermatology offices. Overseeing the daily logistics of clinical partnerships, the Chief Operating Officer ensures that over 200 practice locations receive the necessary support to treat patients effectively. This role involves managing the deployment of radiotherapy equipment and coordinating with medical staff to maintain high standards of care. Joshua Swindle drives efficiency across the organization by streamlining workflows and optimizing the delivery of non-surgical cancer treatment services. By focusing on operational excellence, the Chief Operating Officer facilitates the expansion of the company footprint throughout North American markets. Through constant monitoring of service delivery metrics, Swindle ensures that the company meets the needs of dermatologists and Mohs surgeons. This leadership role remains central to the successful implementation of advanced radiotherapy solutions, directly impacting the quality of care provided to thousands of patients.

Daniel Ladd, the Chief Medical Officer, Center of Excellence at SkinCure Oncology, directs the clinical standards and medical protocols associated with Image-Guided SRT technology. Overseeing the Center of Excellence, the Chief Medical Officer ensures that all partner dermatologists and Mohs surgeons receive comprehensive training and support for non-surgical skin cancer treatment. This role involves establishing best practices for radiotherapy application to guarantee consistent patient outcomes across the national network. Daniel Ladd collaborates with clinical teams to refine treatment methodologies and integrate the latest advancements in oncology care. By maintaining rigorous medical oversight, the Chief Medical Officer upholds the reputation of the company as a provider of high-quality, evidence-based solutions. Through the development of educational programs and clinical resources, Ladd supports the professional growth of partner physicians. This leadership role remains vital to the mission of improving skin cancer care, ensuring that every patient receives effective, specialized treatment within the comfort of a local dermatology office.